Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP) regarding possible violations of federal securities laws. Investors who purchased Simulations Plus securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives. What if I purchased Simulations Plus securities?If you incurred significant losses and want ...

PresentationI'll turn it over to Shawn to give a brief overview of Simulations Plus and the platform, and then we can go through questions as well as any questions that we have from the audience. So over to you, Shawn.Well, thank you, everybody, for being here today. I'm delighted to introduce Shawn O'Connor, who's the CEO of Simulations Plus. Thank you for joining us, Shawn.Shawn O'ConnorChief Executive Officer Very good. Thank you, Mark. Thanks for having us here for the conference. Simulations Plus will ...

PresentationI'll turn it over to Shawn to give a brief overview of Simulations Plus and the platform, and then we can go through questions as well as any questions that we have from the audience. So over to you, Shawn.Well, thank you, everybody, for being here today. I'm delighted to introduce Shawn O'Connor, who's the CEO of Simulations Plus. Thank you for joining us, Shawn.Shawn O'ConnorChief Executive Officer Very good. Thank you, Mark. Thanks for having us here for the conference. Simulations Plus will ...

Simulations Plus (NasdaqGS:SLP) FY Conference September 10, 2025 02:35 PM ET Speaker0Well, thank you everybody for being here today. I'm delighted to introduce Sean O'Connor, who's the CEO of Simulation Plus. Thank you for joining us, Sean. I'll I'll turn it over to Sean to to give a brief overview of of Simulation Plus and and the platform, and then we can go through some questions as well as any questions that we have from the audience. So over to you, Sean.Very good. Thank you, Mark. Thanks for having us ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit. Why Is Simulations Plus being Investigated?Simulations Plus is a software company that develops tools for modeli ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Simulations Plus (SLP) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Simulations Plus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investi ...

Financial Data and Key Metrics Changes - The biosimulation market has historically grown at a 15% CAGR but has fallen below that over the last couple of years, with the company achieving 10% organic growth during this period [15][18] - The company's revenue guidance was adjusted due to project cancellations and delays, impacting the expected growth trajectory [16][18] Business Line Data and Key Metrics Changes - The business is composed of approximately 60% software licensing and 40% consulting services, with the software side remaining relatively unaffected by recent market challenges [17][20] - Renewal rates for software licenses remain consistent at over 90%, with fluctuations primarily due to client bankruptcies and consolidations [20][21] Market Data and Key Metrics Changes - The drug development industry is facing cost constraints and reduced funding, leading to tighter budgets among clients [14][15] - The FDA's recent announcements regarding the reduction of animal testing requirements are seen as a potential tailwind for the biosimulation market, which could enhance growth opportunities [23][24] Company Strategy and Development Direction - The acquisition of Proficiency has expanded the company's total addressable market (TAM) from $4 billion to $8 billion, allowing for increased opportunities in clinical operations [5][6] - The company is focusing on integrating various modeling and simulation techniques to enhance product offerings and cross-selling opportunities [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that the drug development industry does not respond well to surprises, which has led to a slowdown in project approvals and contract negotiations [16][18] - The company anticipates a return to a more steady flow of project requests in fiscal year 2026, with expectations of regaining a growth rate closer to 15% [18][19] Other Important Information - The company is launching a cloud-based platform, Astra Plus, which is expected to enhance functionality and accessibility for clients [33][34] - The integration of AI technology into the company's products is a key focus for future development [31][34] Q&A Session Summary Question: What are the expectations for renewal rates and future fiscal year performance? - Renewal rates are expected to remain stable at over 90%, with the service side impacted by client cancellations but the software side performing well [20][21] Question: How is the FDA's movement away from animal models affecting the company? - The FDA's announcements regarding biosimulation and animal testing are seen as positive developments that could lead to increased adoption of the company's tools [23][24] Question: What is the company's growth formula regarding new and existing clients? - Software revenue typically comes from 80% renewals, 10% upsells, and 10% new clients, with a focus on cross-selling opportunities [29][30]

NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit. Why Is Simulations Plus being Investigated? Simulations Plus is a software company that develops tools for modeli ...

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3] - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, but shortly after, on June 11, 2025, it announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4] - Following the announcement, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4] - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the impairment charge and auditor dismissal [5]